Summary of the Conference Call on Preclinical CRO Industry Industry Overview - The preclinical Contract Research Organization (CRO) sector is experiencing a significant surge in orders, with a full recovery expected by Q4 2025. Orders are projected to increase by tens of percentage points year-on-year in H1 2026, potentially doubling the order value due to both volume and price increases [1][2]. Core Insights and Arguments - **Service Price Recovery**: Rapid recovery in service prices has been noted, particularly in the safety evaluation sector, where discounts have narrowed from 50% to no discount, resulting in year-on-year price increases of several tens of percentage points. This price increase is expected to translate directly into profits [1][2]. - **Monkey Resource Supply Shortage**: A critical factor driving the increase in service prices is the shortage of monkey resources, exacerbated by slow import approval processes. This shortage has led to a dramatic rise in monkey prices, which in turn has pushed up service fees [3]. - **BD Transaction Activity**: The active business development (BD) transactions are concentrating research and development investments in the preclinical phase. High-value orders are expected to be fully reflected in financial reports by Q3 2026, with net profits anticipated to return to 2021 peak levels by Q1 2027 [1][4]. Future Outlook - **Order Sustainability**: There are no immediate concerns regarding order sustainability. Orders are expected to show strong performance in Q1 and Q2 of 2026, with projected year-on-year growth of several tens of percentage points. The overall order amount may double due to the combined effect of increased order volume and service price hikes [4]. - **Profit Margin Impact**: The rapid increase in order prices is expected to significantly enhance profit margins for related companies. The price improvement began in Q3 2025, with discounts narrowing from 50-60% to 80-90%. This price increase is anticipated to be reflected in financial statements starting Q3 2026, with some companies potentially reaching net profit levels close to the peak of 2021 by Q1 2027 [5][6]. Key Companies to Watch - **InnoCare Pharma**: Recommended due to its low correlation with the domestic market and strong order certainty in Q1 and Q2 of 2026. Its smaller market capitalization provides significant upside potential [7]. - **Zhaoyan New Drug**: Despite facing a reduction event, it presents a good entry point. The profit levels in 2027 are expected to match or exceed those of 2021, with considerable room for growth compared to previous peaks [7]. - **Medpace**: As a leading integrated preclinical service provider, it is currently benefiting from the focus on safety evaluation. As the industry continues to improve, its front-end services are expected to gain traction, revealing its performance elasticity [7]. Overall Market Trend - The current market situation is just the beginning, driven by improved BD conditions for innovative drugs in 2025. Although there have been significant stock adjustments due to rising monkey prices and corrections in the innovative drug sector, the current position offers a favorable entry point for investors. Continued healthy development of the Chinese innovative drug industry is expected to benefit domestic CRO companies, with potential for greater valuation expansion if orders remain strong in the second half of the year [8][9].

Core Viewpoint - The logic of multinational pharmaceutical companies "shopping" in the Chinese market is undergoing a subtle differentiation, with some companies focusing on early-stage asset incubation and technology licensing, while others are shifting their attention to collaborations in the later stages of drug pipeline development and commercialization [3][6]. Group 1: Market Dynamics - The first innovative drug for post-operative precision assessment of differentiated thyroid cancer, injection human thyroid-stimulating hormone β (Zesuning®), was prescribed in March at two hospitals in China [3]. - Differentiated thyroid cancer has seen a rapid increase in incidence in China, with over 90% of cases being differentiated thyroid cancer, and a 10-year recurrence rate of 19% post-surgery [3][4]. - The collaboration between Zai Lab and Merck for Zesuning® involved a payment of 250 million yuan for exclusive promotion rights in mainland China [4]. Group 2: Collaboration Trends - Merck's strategy focuses on partnering with projects that are in the later stages of development, indicating a shift towards more cautious and controlled risk in drug licensing agreements [5][6]. - The number and scale of innovative drug licensing transactions initiated by multinational pharmaceutical companies have been increasing, with projections indicating that by 2025, the total value of these transactions in China will exceed $130 billion [6]. Group 3: Challenges and Opportunities - Despite the growth in licensing transactions, there is a notable "return rate" of 40% for collaborations initiated in 2020, highlighting challenges in clinical data expectations and strategic shifts [6]. - Zai Lab's collaboration with Merck is focused on the domestic market, aiming to address unmet clinical needs in China, where over 500,000 new thyroid cancer patients are diagnosed annually [7]. - The need for partnerships arises from the limited commercialization capabilities of many small and medium-sized biotech companies in China, which necessitates collaboration with firms that have established commercial networks [7][8].

Core Insights - The article discusses the insights from Yang Yunxia, a partner at Sequoia China, highlighting that China's biopharmaceutical innovation has become a significant player in the global industry and a source of world innovation [3][6]. Group 1: Market Trends and Investment Directions - The biopharmaceutical sector in China is expected to continue its growth, with a focus on major disease areas such as oncology, autoimmune diseases, neurology, and metabolism, while also addressing underrepresented fields like gynecology, nephrology, and ophthalmology [3][8]. - The transaction value of Chinese innovative drug business development (BD) has increased tenfold over the past five years, indicating a growing recognition and willingness of multinational corporations (MNCs) to pay premiums for Chinese assets [3][9]. - The market is experiencing a resurgence, with increased enthusiasm from early-stage entrepreneurs and active participation from investors, making 2025 a fruitful year for the industry [5][6]. Group 2: Product Development and Innovation - There is an ongoing evolution in drug molecular forms, with advancements expected in antibody-drug conjugates (ADCs) and small nucleic acids, moving towards dual-target and dual-toxin formats [3][8]. - The trend of Chinese innovative drugs gaining international recognition is anticipated to continue, with more overseas companies showing interest in Chinese assets and establishing collaborations with local investment institutions [9][10]. Group 3: Future Outlook and Strategic Focus - The investment strategy of Sequoia China remains consistent, focusing on innovation and maintaining long-term relationships with early-stage companies and entrepreneurs [7][10]. - The expectation for 2026 is to see more entrepreneurs with a global perspective and competitive products entering the market, reflecting a shift in focus towards genuine global innovation [11].

Core Viewpoint - The keyword for the stock market in 2025 is expected to be "innovative drugs," with significant stock price increases driven by the potential of in-development innovative drugs and BD (business development) transactions rather than traditional revenue from already marketed drugs [1] Group 1: BD Transactions - In 2025, China's innovative drug BD transaction total exceeded $100 billion, with notable orders reaching $10 billion, and upfront payments from multinational pharmaceutical companies reaching a new high of $1.25 billion [1] - Landmark transactions include a $13 billion collaboration between Qihuang Dejian and Biohaven/AimedBio in January, marking a milestone for China's ADC technology [2] - In May, 3SBio's deal with Pfizer exceeded $6 billion, setting a record for upfront payments in China at $1.25 billion, highlighting the value of both first-in-class and fast-follow drugs [2] - In July, a $12 billion strategic partnership between Hengrui Medicine and GlaxoSmithKline showcased the depth of early-stage pipelines in leading Chinese pharmaceutical companies [2] - In October, Innovent Biologics and Takeda's collaboration worth $11.4 billion included a cost-sharing model for global R&D, enhancing operational capabilities for future international ventures [2] Group 2: Milestone Payments and Emerging Fields - Several past BD transactions reached milestone payments in 2025, including a $300 million payment to China National Pharmaceutical's subsidiary from Merck and a $250 million payment to Bairui Tianheng from Bristol-Myers Squibb [3] - The focus of BD transactions is shifting from oncology to other therapeutic areas, with autoimmune diseases, metabolism, and central nervous system disorders emerging as new hot fields [3] - Notable deals include the global rights licensing of BTK inhibitor Orelabrutinib for multiple sclerosis by Nocera Biopharma, with a potential total transaction value exceeding $2 billion [3] - The metabolic field is gaining traction, driven by global weight loss trends, with several companies entering into licensing agreements for GLP-1 targeted drugs [3] Group 3: Independent Clinical Trials and Regulatory Approvals - Numerous innovative drug companies in China are advancing their own overseas clinical trials, achieving significant progress [4] - In early 2025, Dize Pharmaceutical's lung cancer targeted drug received priority review from the FDA and was approved in July, becoming the first globally innovative drug independently developed in China to gain approval in the U.S. [4] - Other advancements include breakthrough therapy designations for CS0159 by Kexi Kedi and a Phase III trial approval for a recombinant human albumin injection by Heyuan Biopharma [4] - These developments indicate that the Chinese innovative drug industry is becoming a significant force in global innovation, transitioning from fast-following to original innovation and integrating deeply into the global value chain [4]

Industry Overview - The business development (BD) transactions for innovative drugs in China are experiencing significant growth, with expectations for further improvement in 2026 [2] - Multinational pharmaceutical companies (MNCs) have shifted their perspective towards China, now showing confidence in Chinese data and increasing interest in early-stage pipelines, not just clinical assets [2] - The regulatory environment for innovative drugs in China is improving, allowing for the possibility of global first approvals within China [2] Key Developments in 2026 - Significant advancements are anticipated in two areas: small nucleic acid drugs, which show promising clinical effects for chronic diseases, and T-cell engagers (TCEs), which are expected to make notable progress, particularly in treating small cell lung cancer [3] - The company Valiant Biopharma's key focus will be on its core pipeline LBL-024, a PD-1/41BB dual antibody, which is positioned as a foundational anti-tumor drug [3][4] Upcoming Milestones - The company plans to submit LBL-024 for market approval in China by mid-2026, with an expected approval in 2027 [4] - Phase II clinical trial results for LBL-024 are anticipated in 2026, indicating its broad-spectrum capabilities as an anti-tumor medication [4] - Four unique first-in-class drugs are being prepared for submission for new drug clinical trial licenses, expected to enter clinical development between 2026 and 2027 [5] Future Business Development - The company aims to enhance its BD efforts, emphasizing that success in BD will ultimately depend on the strength of its pipeline [6] - Valiant Biopharma is expected to become a significant player in the Chinese innovative drug industry regarding BD transactions [6]

Core Insights - The Chinese innovative drug industry is entering a new decade of development in 2025, with a significant increase in business development (BD) transactions, reaching a total value of $135.655 billion and 157 transactions, both setting historical records, indicating the growing global appeal of Chinese innovative drugs [1] - Milestone payments from previously established collaborations are beginning to materialize, providing cash flow relief for companies and marking substantial progress in global development [1] - However, potential risks associated with BD collaborations are emerging, including the premature termination of agreements and disputes leading to arbitration or litigation, signaling a need for caution in the industry [1] Industry Trends - The surge in BD transactions in 2025 is driven by the long-accumulated innovative potential of China's biopharmaceutical sector, with expectations for continued growth in cross-border transactions between China and the US/Europe [2] - The BD trend began in 2022, but many companies have not yet experienced the full lifecycle of BD transactions, leading to potential undisclosed issues in long-term performance [2] - The period from 2026 to 2028 may see an increase in BD disputes, as the industry transitions from rapid growth to a more regulated and mature phase [2] Financial Highlights - In May 2025, a record-breaking upfront payment of $12.5 billion was secured by a collaboration between Sangamo Therapeutics and Pfizer, with potential total payments reaching $48 billion [3] - In July 2025, China National Pharmaceutical Group announced a $300 million milestone payment from Merck for a collaboration on a PD-1/VEGF dual antibody [3] - In October 2025, a $250 million milestone payment was triggered for a collaboration between SystImmune and Bristol-Myers Squibb, marking the largest single milestone payment for an ADC asset disclosed in China [3] Payment Structures - The "upfront payment + milestone + sales royalty" model remains the dominant approach for Chinese companies in BD transactions, but only 22% of biopharmaceutical companies achieved milestone events by mid-2025, a decrease from previous years [4] - Among 128 transactions with at least one milestone node, 45% did not generate any revenue, highlighting the uncertainty of milestone payment realizations [4] - Increasing the proportion of upfront payments to secure immediate cash flow has become a consensus among companies to mitigate risks [4] Contractual Strategies - Companies are advised to enhance negotiation strategies by creating competitive environments and optimizing milestone payment terms to reduce ambiguity and disputes [5][6] - Specific, quantifiable conditions for milestone payments should be established to minimize subjective interpretations and risks of disputes [5] - The interrelation of contractual terms should be considered to avoid imbalances in rights and obligations, which could lead to significant disagreements during project execution [6] Legal Considerations - The potential for a wave of litigation in the BD sector is rising, driven by long-term contracts and various uncertainties affecting performance [7] - Companies often prioritize commercial negotiations to resolve disputes, but if unsuccessful, they must rely on the agreed dispute resolution mechanisms, emphasizing the importance of precise contract language [7][8] - Early identification of dispute trajectories and effective crisis management can significantly influence the outcome of legal proceedings [8] Future Outlook - As of January 2026, 17 BD transactions have occurred, totaling $133.61 billion, with significant projects continuing to emerge [9] - The ADC sector, small nucleic acid drugs, and in vivo CAR-T therapies are expected to be key areas for BD transactions in the next 1-2 years, with a shift in focus towards clinical data validation [10] - The industry is moving towards a more mature and regulated phase, with an emphasis on risk awareness and compliance as essential elements for successful cross-border BD initiatives [10]

Core Insights - The strategic collaboration and licensing agreement between CSPC Pharmaceutical Group and AstraZeneca for the development of innovative long-acting peptide drugs has a potential transaction value of up to $18.5 billion, setting a new record for BD transactions among Chinese pharmaceutical companies [2][13]. Group 1: Transaction Details - The agreement includes an upfront payment of $1.2 billion and up to $17.3 billion in milestone payments [2][13]. - This transaction is part of a broader trend where multiple innovative drug BD transactions have been completed since the beginning of 2026, indicating a positive trend for Chinese innovative drugs going global [13][20]. Group 2: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown strong performance, leading its peers since 2025, with a return of 75.03% [4][17]. - The index is characterized by high purity, elasticity, and sharpness, demonstrating strong aggressiveness in the rebound of the innovative drug market [4][17]. Group 3: Historical Context - In 2025, the total value of innovative drug BD outbound licensing transactions from China reached $135.655 billion, with a total of 157 transactions, both setting historical highs [20][21]. - The historical annual returns for the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index from 2021 to 2025 were -22.72%, -16.48%, -19.76%, -14.16%, and 66.32% respectively [6][18].

Core Viewpoint - The report from CITIC Securities indicates that while industrial production remains resilient and exports are growing rapidly, domestic demand indicators such as consumption and investment are still weak, highlighting a characteristic of "strong production versus weak demand" throughout the previous year [1] Economic Environment - The current macroeconomic environment shows similarities to the investment peak period of 2020-2021, with interbank interest rates at their lowest levels since 2020 [1] - The combination of weak macro demand and loose liquidity is expected to favor structural investment opportunities in certain sectors [1] Sector Insights - In the technology sector, AI semiconductors and new energy are identified as the core areas of current prosperity, with strong policy support for AI applications and accelerated commercialization [1] - The global capacity planning for space photovoltaics has exceeded expectations, and technological breakthroughs are opening up trillion-dollar markets [1] - The innovative drug sector is seeing value realization driven by business development transactions, clinical breakthroughs, and new drug approvals [1] Resource Sector - The non-ferrous metals industry has the highest forecasted performance improvement rate for 2025, with attention on the subsequent transmission of prosperity to the energy and machinery sectors [1] - As monetary easing continues, funds are expected to gradually shift from the financial system to the real economy, benefiting sectors such as non-ferrous metals, chemicals, machinery, and consumer goods [1] - Since December 2025, the South China Metal Index has risen by 12.5%, while the energy and industrial product indices have only increased by around 7%, suggesting better investment value in the current market [1]

Core Viewpoint - The collaboration between AbbVie and Rongchang Biologics marks a significant shift in the global oncology treatment landscape, highlighting the trend of Chinese innovative drug companies partnering with multinational giants for drug development and commercialization [1][2]. Group 1: Collaboration Details - AbbVie and Rongchang Biologics signed an exclusive licensing agreement for the development, production, and commercialization of RC148, a bispecific antibody targeting PD-1 and VEGF [1]. - Rongchang Biologics will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in milestone payments, along with a tiered royalty on net sales outside Greater China [1][2]. Group 2: Market Implications - This deal exemplifies the "China innovation + global market" model, allowing Rongchang Biologics to secure cash flow and accelerate clinical trials for RC148 while focusing on the Chinese market [2]. - AbbVie aims to enhance its product portfolio in immuno-oncology, particularly in the emerging PD-1/VEGF bispecific antibody space, which could synergize with existing antibody-drug conjugates (ADCs) and immuno-oncology (IO) drugs [2]. Group 3: Competitive Landscape - The PD-1/VEGF bispecific antibody represents a new class of cancer therapies that may overcome tumor resistance mechanisms by simultaneously blocking PD-1 and VEGF [3][5]. - Chinese companies are leading in this field, with notable products like Ak112/Ivonescimab and SSGJ707 entering clinical trials, indicating a competitive landscape for PD-1/VEGF bispecific antibodies [3][4]. Group 4: Industry Trends - The surge in business development (BD) transactions in the PD-1/VEGF bispecific antibody sector reflects increasing interest from multinational pharmaceutical companies in Chinese innovative drug assets [6]. - In 2025, the total value of Chinese innovative drug licensing transactions exceeded $130 billion, surpassing the U.S. for the first time, indicating a significant shift in the global pharmaceutical landscape [7][8]. Group 5: Future Outlook - The increasing recognition of Chinese innovative drugs is attributed to their rapid development and the ability to meet unmet clinical needs, enhancing their bargaining power in international collaborations [8][9]. - The industry is witnessing a transition from following to leading in drug innovation, with a clear direction for the future of Chinese pharmaceutical development [10].

Core Insights - China's innovative drug transaction value has surpassed that of the United States, indicating growing global recognition of domestic innovations [1][4] - The total transaction amount for outbound licensing of innovative drugs from China is projected to reach $135.655 billion by December 31, 2025, with a significant increase in both upfront payments and transaction numbers compared to 2024 [1][4] - The surge in outbound licensing reflects the international community's acknowledgment of the value of Chinese innovative drugs, driven by reforms in drug approval processes and supportive policies [1][4] Transaction Overview - In 2025, the total amount of outbound licensing transactions for innovative drugs from China exceeded $1,300 billion, with over 150 transactions, significantly surpassing the 2024 figures of $519 billion and 94 transactions [4][5] - The first transaction of 2025 involved Innovent Biologics partnering with Roche, receiving an upfront payment of $80 million and potential milestone payments of up to $1 billion [4] - Notable transactions include a record upfront payment of $1.25 billion from 3SBio to Pfizer for a global licensing agreement, and a total transaction amount exceeding $12 billion with GSK [5] Market Dynamics - The demand for Chinese innovative assets is expected to persist as multinational corporations (MNCs) face patent cliffs and cost-cutting pressures [8][9] - The global pharmaceutical supply chain is undergoing significant adjustments, with MNCs increasingly looking to China for early-stage innovative pipelines due to cost-effectiveness and potential superior outcomes [9][10] - The shift in business development (BD) models is evident, with a move towards co-development and co-commercialization agreements, allowing Chinese companies to play a more active role in global markets [10][11] Industry Trends - China's innovative drug pipeline accounts for approximately 30% of the global total, with significant achievements in key therapeutic areas such as PD-1/VEGF bispecific antibodies [8] - The industry is transitioning from a "fast-follower" to a "first-in-class" model, emphasizing the importance of clinical value and unmet medical needs [6][15] - The approval of 76 innovative drugs in 2025, with a high percentage being domestically developed, highlights the growing capabilities of Chinese pharmaceutical companies [5][6] Future Outlook - The innovative drug sector in China is expected to face challenges in maintaining the momentum of BD transactions, with concerns about sustainability and the potential for a slowdown in transaction values [14][15] - The focus for 2026 will likely shift towards solidifying clinical value and addressing unmet needs, particularly in oncology and autoimmune diseases [15][16] - The Chinese regulatory body plans to implement more measures to support the rapid development of innovative drugs, indicating a commitment to fostering industry growth [15][16]